Fig. 1
Functional outcome and survival of SOD-1G93A mice after BMMC therapy. a, b Rotarod test, c, d hanging-wire test, e, f motor-score test, and g, h cumulative survival. SOD-1G93A mice were injected with BMMCs or saline at two different time points: presymptomatic phase (9 weeks old a, c, e, g) and symptomatic phase (14 weeks old b, d, f, h). The animals that received the treatment in week 9 showed a 2-week delay in the functional loss in the rotarod and hanging-wire tests. In the motor-score analyses, the saline-injected animals in week 9 showed a decline in week 14, while the BMMC-treated animals showed a decline in week 15. No differences were observed between the saline-injected and BMMC-injected animals in week 9 in the cumulative survival. The therapy in week 14 did not show an effect in any analysis performed. Arrows indicate week of treatment. *WT vs. saline (p <0.05), #WT vs. BMMC (p <0.05). BMMC bone marrow-derived mononuclear cells, SOD1 Cu/Zn superoxide dismutase 1, WT wild-type